Compared with H1 20, AstraZeneca witnessed a pertinent slowdown in Q3 sales growth. Growth was again driven by Oncology and aptly supported by the New CVRM, while R&I was weak. However, the recovery in profitability was sustained – especially on the back of sales & marketing activities of the earlier years yielding impressive results. While material Chinese sales exposure is a critical advantage, especially at a time when COVID-19 cases are again spiking in the developed world, Astra seems expen ....
09 Nov 2020
Material Q3 growth moderation, but profitability improvement continued
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Material Q3 growth moderation, but profitability improvement continued
AstraZeneca PLC (AZN:LON) | 10,689 0 0.0% | Mkt Cap: 165,702m
- Published:
09 Nov 2020 -
Author:
Surbhit Gupta -
Pages:
5
Compared with H1 20, AstraZeneca witnessed a pertinent slowdown in Q3 sales growth. Growth was again driven by Oncology and aptly supported by the New CVRM, while R&I was weak. However, the recovery in profitability was sustained – especially on the back of sales & marketing activities of the earlier years yielding impressive results. While material Chinese sales exposure is a critical advantage, especially at a time when COVID-19 cases are again spiking in the developed world, Astra seems expen ....